{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:43:31Z","timestamp":1790419411213,"version":"4.1.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T00:00:00Z","timestamp":1658188800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Preventive Medicine Reports"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.pmedr.2022.101923","type":"journal-article","created":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T02:20:36Z","timestamp":1658456436000},"page":"101923","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Cost-effectiveness of herpes zoster vaccines in the U.S.: A systematic review"],"prefix":"10.1016","volume":"29","author":[{"given":"Neil R.","family":"Meredith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward P.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pmedr.2022.101923_b0005","doi-asserted-by":"crossref","unstructured":"Carpenter CF, Aljassem A, Stassinopoulos J, Pisacreta G, Hutton D. A cost-effectiveness analysis of an adjuvanted subunit vaccine for the prevention of herpes zoster and post-herpetic neuralgia. Oxford University Press US; 2019:ofz219.","DOI":"10.1093\/ofid\/ofz219"},{"issue":"33","key":"10.1016\/j.pmedr.2022.101923_b0010","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.1016\/j.vaccine.2018.07.005","article-title":"Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States","volume":"36","author":"Curran","year":"2018","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.pmedr.2022.101923_b0015","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1080\/21645515.2018.1558689","article-title":"Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live","volume":"15","author":"Curran","year":"2019","journal-title":"Hum. Vacc. Immunother."},{"issue":"3","key":"10.1016\/j.pmedr.2022.101923_b0020","doi-asserted-by":"crossref","first-page":"103","DOI":"10.15585\/mmwr.mm6703a5","article-title":"Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines","volume":"67","author":"Dooling","year":"2018","journal-title":"Morb. Mortal. Wkly Rep."},{"issue":"2","key":"10.1016\/j.pmedr.2022.101923_b0025","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jval.2013.02.002","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS)\u2013explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force","volume":"16","author":"Husereau","year":"2013","journal-title":"Value Health"},{"issue":"22","key":"10.1016\/j.pmedr.2022.101923_b0030","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.pmedr.2022.101923_b0035","doi-asserted-by":"crossref","first-page":"489","DOI":"10.7326\/M15-0093","article-title":"Cost-effectiveness of herpes zoster vaccine for persons aged 50 years","volume":"163","author":"Le","year":"2015","journal-title":"Ann. Intern. Med."},{"issue":"2","key":"10.1016\/j.pmedr.2022.101923_b0040","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11606-016-3844-6","article-title":"Determining the optimal vaccination schedule for herpes zoster: a cost-effectiveness analysis","volume":"32","author":"Le","year":"2017","journal-title":"J. Gen. Intern. Med."},{"issue":"6","key":"10.1016\/j.pmedr.2022.101923_b0045","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.amepre.2017.08.029","article-title":"Cost effectiveness of a shingles vaccine booster for currently vaccinated adults in the U.S.","volume":"53","author":"Le","year":"2017","journal-title":"Am. J. Prev. Med."},{"issue":"2","key":"10.1016\/j.pmedr.2022.101923_b0050","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1001\/jamainternmed.2017.7431","article-title":"Cost-effectiveness of the adjuvanted herpes zoster subunit vaccine in older adults","volume":"178","author":"Le","year":"2018","journal-title":"JAMA Intern. Med."},{"issue":"9","key":"10.1016\/j.pmedr.2022.101923_b0055","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1001\/jamainternmed.2018.3200","article-title":"Cost-effectiveness of the recommendations of the Advisory Committee on Immunization Practices for the recombinant adjuvanted zoster subunit vaccine","volume":"178","author":"Le","year":"2018","journal-title":"JAMA Intern. Med."},{"issue":"4","key":"10.1016\/j.pmedr.2022.101923_b0060","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jval.2021.01.002","article-title":"Critical appraisal of systematic reviews with costs and cost-effectiveness outcomes: An ISPOR good practices task force report","volume":"24","author":"Mandrik","year":"2021","journal-title":"Value Health"},{"issue":"6","key":"10.1016\/j.pmedr.2022.101923_b0065","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jpain.2005.01.359","article-title":"Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey","volume":"6","author":"Oster","year":"2005","journal-title":"The Journal of pain"},{"key":"10.1016\/j.pmedr.2022.101923_b0070","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. PLoS Med. Mar 2021;18(3):e1003583. doi:10.1371\/journal.pmed.1003583.","DOI":"10.1371\/journal.pmed.1003583"},{"issue":"6","key":"10.1016\/j.pmedr.2022.101923_b0075","doi-asserted-by":"crossref","first-page":"380","DOI":"10.7326\/M18-2347","article-title":"A cost-effectiveness analysis of vaccination for prevention of herpes zoster and related complications: input for national recommendations","volume":"170","author":"Prosser","year":"2019","journal-title":"Ann. Intern. Med."},{"issue":"3","key":"10.1016\/j.pmedr.2022.101923_b0080","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1056\/NEJMcp1302674","article-title":"Herpes zoster","volume":"369","author":"Solomon","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pmedr.2022.101923_b0085","doi-asserted-by":"crossref","first-page":"105860","DOI":"10.1016\/j.ypmed.2019.105860","article-title":"Cost-effectiveness of a comprehensive immunization program serving high-risk, uninsured adults","volume":"130","author":"Wilson","year":"2020","journal-title":"Article Prevent. Med."},{"issue":"11","key":"10.1016\/j.pmedr.2022.101923_b0090","first-page":"1341","article-title":"A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction","volume":"82","author":"Yawn","year":"2007","journal-title":"Elsevier"}],"container-title":["Preventive Medicine Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211335522002303?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211335522002303?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T15:05:17Z","timestamp":1761923117000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211335522002303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":18,"alternative-id":["S2211335522002303"],"URL":"https:\/\/doi.org\/10.1016\/j.pmedr.2022.101923","relation":{},"ISSN":["2211-3355"],"issn-type":[{"value":"2211-3355","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of herpes zoster vaccines in the U.S.: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Preventive Medicine Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pmedr.2022.101923","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101923"}}